News >

Venetoclax/Navitoclax Regimen Is Effective, Safe in Lymphoblastic Lymphoma and ALL

Jason Harris
Published: Friday, Sep 14, 2018

Andrew Hantel, MD

Andrew Hantel, MD
Phase I data showed that combining the BCL-2 inhibitor venetoclax (Venclexta) and the investigational small molecule inhibitor navitoclax (ABT-263) plus chemotherapy demonstrated encouraging responses and tolerability in patients with relapsed/refractory acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LL).


  1. Hantel A, Wynne J, Lacayo N, et al. Safety and efficacy of the BCL inhibitors venetoclax and navitoclax in combination with chemotherapy in patients with relapsed/refractory acute lymphoblastic leukemia and lymphoblastic lymphoma. Clin Lymphoma Myeloma Leuk. 2018;18(suppl; Abstract ALL-131).
  2. Wilson WH, O’Connor OA, Czuczman MS, et al. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol. 2010;11(12):1149-59. doi: 10.1016/S1470-2045(10)70261-8.
  3. Seymour JF, Kippes TJ, Eichhorst B, et al. Venetoclax–rituximab in relapsed or refractory chronic lymphocytic leukemia [published online March 22, 2018]. N Engl J Med. 2018; 378:1107-1120. doi: 10.1056/NEJMoa1713976.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication